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Abstract
In an effort to find chemicals inhibiting the enzymatic activity of the hepatitis C virus (HCV) NS5B polymerase, a series
of thiobarbituric acid derivatives were selected from a library provided by Korea Research Institute of Chemical
Technology and characterized. The selected compounds exhibited IC50 values ranging from 1.7 to 3.8 μM, and EC50
values ranging from 12.3 to 20.7 μM against NS5B polymerase of type 1b strain. They showed little effect against type
2a polymerase. One of the compounds, G05, was selected and further characterized. It inhibited the synthesis of RNA
by recombinant HCV NS5B polymerase in a dose dependent manner. The CC50 value was 77 μM. The inhibition was
in a noncompetitive manner with the substrate UTP. The compound did not inhibit the elongation step of RNA
synthesis in a single-cycle processive polymerization assay. It inhibited the binding of NS5B polymerase to the
template RNA in a dose-dependent manner.
Findings
The hepatitis C virus causes chronic hepatitis in human,
and an estimated 170 million people are infected world-
wide [1,2]. However, no vaccine has yet been successful,
and no specific inhibitor is currently available other
than interferon alpha and ribavirin, where the response
rate is lower than 50% and side effects have been
reported [3,4].
Nonstructural protein 5B is responsible for HCV geno-
mic replication [5,6], which made it a major target for the
development of an antiviral therapy and many compounds
have been reported to inhibit this target. Non-nucleoside
inhibitors (NNIs) bind to an allosteric site and cause a
change in the conformation of the active site in the
enzyme, thereby inhibiting the initiation step, whereas pyr-
ophosphate mimics bind to catalytic metal ions in the
active site of the protein, thereby inhibiting enzymatic
activity. Many NNIs have already been reported. One
example is benzimidazoles, which bind to the thumb
domain of NS5B [3,7-10], while another is thiophene deri-
vatives which are reversible allosteric inhibitors that also
bind to the thumb domain [11], yet the binding sites in
the thumb domain for the two inhibitors are different.
X ray crystallographic studies have revealed that phenyla-
lanine and dihydropyranone scaffold inhibitors bind to the
same site in NS5B, although they have different chemical
structures [12,13]. Benzothiadiazine scaffold inhibitors are
also known to inhibit the initiation step of RNA synthesis
[14,15], yet the binding site and inhibition mechanism are
believed to be different from others [16].
While screening a chemical library provided by Korea
Research Institute of Chemical Technology, several thio-
barbituric acid derivatives were found by the current
authors to have inhibitory effects on the HCV NS5B
polymerase. This study reports on the characterization
of inhibitory mechanism by the compounds.
6,500 compounds with representative chemical struc-
tures from the Korea Research Institute of Chemical
Technology (KRICT) were screened for their inhibitory
effect on the HCV NS5B polymerase. A bacterial cell-
based assay was used for screening as described [17].
The structures of the hit compounds are shown in
Additional file 1. All 4 compounds were thiobarbituric
acid derivatives. The inhibition of RNA synthesis by
these compounds was biochemically tested in a [
32P]-
UMP incorporation assay with a purified recombinant
NS5B and poly(A)-oligo(dT) template. Potent inhibition
against 1b type polymerase (Con-1) was exhibited with
IC50 values between 1.7 and 3.8 μM. But essentially no
inhibition was observed against 2a (JFH-1) type poly-
merase. The inhibitory effects on the 1b type HCV
subgenomic RNA replicon [18] was measured using a
real-time RT-PCR analysis of plus-strand RNA
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any medium, provided the original work is properly cited.(Additional file 1). The EC50 values ranged from 12.3 to
21 μM, yet the level of cellular GAPDH RNA was not
changed at these concentrations. The EC50 values were
positively correlated with the IC50 values, suggesting
there was little variation in the membrane permeability
of each compound. In the presence of the compounds
naïve Huh-7 cells showed an altered viability as mea-
sured by a standard MTT assay. The CC50 of G05 com-
pound for naïve Huh-7 cells was 77 μM( F i g u r e1 ,a ) .
The G05 compound was not a nucleoside analogue, sug-
gesting that it may include a noncompetitive mechanism
of inhibition. That was confirmed by measuring the
[
32P]-UMP incorporation by recombinant NS5B (C-
terminal 21 amino-acids deleted form) in the presence
of various concentrations of G05. The Km for UTP
remained unchanged while the Vmax decreased
when the concentration of G05 increased (Figure 1, b).
The Lineweaver-Burk plot (Figure 1, c) suggests that the
compound may interact with the HCV NS5B polymer-
ase at a site other than the UTP binding site.
As a noncompetitive inhibitor, G05 may either inhibit
the initiation step or the elongation step of the polymer-
ization reaction. We tested if the compound inhibited
the initiation step of RNA synthesis using heparin.
Heparin is a known polymerase inhibitor trapping free
enzyme dissociated from the template [19] and was used
to create a single processive reaction in this experiment.
The NS5B and poly(A)-oligo(dT) template were mixed
a n dp r e i n c u b a t e da tr o o mt e m p e r a t u r ef o r9 0m i n u t e s
before adding 2.5 μg of heparin, 10 μCi of a-[
32-P]-
UTP, and 50 μM UTP for the polymerization reaction.
Thereafter, the G05 compound was added and the reac-
tion mixture was further incubated and visualized after
running on a polyacrylamide gel. Since the nucleotide
Figure 1 Mode of inhibition by G05 compound. (a) Naïve Huh7 cells were treated with various concentrations (up to 100 μM) of G05
compound and the viability was measured with standard MTT assay. (b) Huh7 cells harboring the HCV subgenomic replicon were treated with
G05 compound at a concentration of 5 15 or 30 μM. After 72 hours of incubation the amounts of (+) and (-) sense replicon RNA were measured
using a real-time RT-PCR. (b) [
32P]-UMP incorporation measured after 90 minutes of incubation in the presence of G05 at 0 1.7 and 13.5 μMi n
concentration. (c) The same assay with G05 at 0.1 0.25 and 0.5 μM in concentration and displayed as a Lineweaver-Burk plot. [I] concentration of
G05 compound.
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synthesis could only be measured from the preformed
template-enzyme complex. In the presence of an
increasing concentration of the G05 compound, the
amount of newly synthesized RNA did not change
(Figure 2, a), which suggests that the compound inhib-
ited the initiation step of RNA synthesis rather than the
elongation step. In the absence of heparin, the com-
pound inhibited RNA synthesis in a dose-dependent
manner (Figure 2, b). The inhibition mode was further
supported by an initiation step assay. Inhibition of bind-
ing between recombinant NS5B and template RNA
was measured as follows; purified recombinant NS5B
was preincubated with G05 at various concentrations.
In vitro transcribed 3’ UTR RNA was added to each
reaction and incubated before pulldown with Ni-NTA
agarose beads (Qiagen, USA). In the presence of an
increasing concentration of the compound, the binding
of NS5B to the template RNA decreased dose-depen-
dently (Figure 2, b), showing a direct inhibition in the
initiation step.
The HCV NS5B polymerase is a well characterized
enzyme and a druggable target based on the identifica-
tion of at least three allosteric binding pockets in addi-
tion to the active site [20]. Accordingly, when screening
a chemical library against HCV NS5B, we found a series
of thiobarbituric acid compounds to be potent inhibitors
of HCV NS5B polymerase. Based on the data presented
in this study, the compound would appear to bind to an
allosteric site in the enzyme and inhibit the initiation
step of RNA synthesis in a noncompetitive manner. In
addition to NS5B, the HCV replicase complex is also
known to include other viral proteins, such as NS3,
NS4A, and NS5A [21]. Plus, various cellular factors have
also been suggested to be involved [22]. However, in the
present results, G05 was found to be active against the
purified recombinant NS5B in a biochemical enzyme
assay, suggesting a direct interaction of the compound
with the enzyme rather than an indirect influence due
to interactions with cofactors. The compound was also
active in a subgenomic replicon cell-based assay, mean-
ing that it exerted the same effect in a cellular environ-
m e n t .T h e yw e r ea b l et op a s st h r o u g ht h ec e l l u l a r
membrane and reach the perinuclear region where HCV
replicase complex was reported to localize [23]. This
study may provide some useful clues for development of
antiviral therapy for hepatitis C virus.
Additional material
Additional file 1: Chemical structures and inhibitory effects of
selected compounds. * The IC50 was measured by a [
32P]-UMP
incorporation assay using poly(A)-oligo(dT) template and recombinant
NS5B and represents the concentration of the inhibitor showing a 50%
reduction in the recombinant NS5B polymerase activity. Unit = μM. # The
EC50 was measured by real-time RT-PCR analysis and represents the
concentration of the inhibitor showing 50% reduction in the RNA level in
a Huh7 cell harboring the HCV subgenomic replicon. Unit = μM.
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